Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

The UWMDI is the first of its kind in the Pacific Northwest, integrating state-of-the-art research programs with superb care for patients with diabetes, obesity and their complications ...

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...